Merck KGaA 보도자료

2023년 2월 14일 08:55

New Analyses Reinforce Survival Benefit of BAVENCIO First-Line Maintenance Treatment in Patients With Advanced Urothelial Carcinoma

Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced findings of a new analysis of long-term follow-up data from the Phase III JAVELIN Bladder 100 trial. These analyses reinforce the proven survival benefits of...

2022년 12월 23일 09:25

Merck Announces Collaboration with Mersana Therapeutics to Develop Novel Immunostimulatory Antibody-Drug Conjugates

Merck, a leading science and technology company, today announced a research collaboration and commercial license agreement with Mersana Therapeutics, Inc., Cambridge, Massachusetts, USA to discover novel antibody-drug conjugates (ADCs) leveraging ...

2022년 11월 22일 13:45

Merck Aims to Double R&D Productivity in Oncology, Neurology and Immunology to Deliver More Medicines to Patients Faster

Merck, a leading science and technology company, today shared updates on the company’s healthcare research and development strategy, aimed at doubling R&D productivity. To achieve the goal of introducing one new product or major indication every 1...

2022년 10월 26일 17:25

Merck Showcases Depth of MS Portfolio at ECTRIMS Supporting Commitment to Advancing MS Care

Merck, a leading science and technology company, today announced it will present 39 abstracts at the 38th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), being held October 26-28, 2022 in Amsterdam, t...

2022년 10월 26일 16:57

Merck Highlights New Data for Evobrutinib, First BTKi to Demonstrate Sustained Clinical Benefit for People with RMS through Three and a Half Years of Treatment

Merck, a leading science and technology company, today announced findings which demonstrated that annualized relapse rates (ARR) remained low and Expanded Disability Status Scale (EDSS) scores were stable in people with relapsing multiple sclerosi...

2022년 9월 22일 15:00

Merck Enters Collaboration and Option to License Agreement with Nerviano Medical Sciences to Develop Next-Generation PARP1 Selective Inhibitor

Merck, a leading science and technology company, today announced a collaboration agreement with licensing option with Nerviano Medical Sciences S.r.l. (NMS) for the next-generation highly selective and brain-penetrant PARP1 (poly (ADP-ribose) poly...

2022년 9월 8일 16:50

Xevinapant Five-Year Data Show Survival Rate Nearly Doubled in Patients with Unresected LA SCCHN, When Added to Standard of Care

Merck, a leading science and technology company, today announced that the IAP (inhibitor of apoptosis protein) inhibitor xevinapant (formerly known as Debio 1143) plus chemoradiotherapy (CRT) markedly improved long-term efficacy outcomes in patien...

2022년 9월 8일 16:50

Merck to Highlight Data at ESMO 2022 with Potential for Transformative Impact on Cancer Patients

Merck, a leading science and technology company, today announced the latest research from the Company’s oncology portfolio and pipeline to be presented at this year’s European Society of Medical Oncology (ESMO) Annual Meeting, September 9-13, 2022...

2022년 6월 7일 11:30

Merck Advances Development Programs in Oncology Focusing on Novel Mechanisms and Pathways

Merck, a leading science and technology company, today provided an update on the progress of the company’s innovative oncology development pipeline focused on DNA damage biology. With clinical programs designed to further advance standards of care...

2022년 5월 27일 10:10

Merck to Present Latest Research From Oncology Portfolio at ASCO 2022

Merck, a leading science and technology company, today announced the latest research representing the Company’s innovative oncology portfolio has been accepted for presentation at this year’s American Society of Clinical Oncology (ASCO) Annual Mee...

2022년 4월 4일 09:30

Merck Shares Advances in MS Portfolio with Key Efficacy and Safety Data at AAN 2022

DARMSTADT, Germany--(BUSINESS WIRE)-- Merck, a leading science and technology company, today announced 13 abstracts from the Company’s multiple sclerosis (MS) portfolio will be presented at the 2022 American Academy of Neurology (AAN) Annual Meeti...

2022년 3월 2일 10:05

Glucophage® Is the First Oral Diabetes Treatment Approved in Europe for Use During Pregnancy

Merck, a leading science and technology company, today announced in a European worksharing procedure (WSP) an extension to the label for metformin products in the EU - Glucophage® (metformin hydrochloride [HCL] immediate release), Glucophage XR® (...

2022년 2월 25일 09:25

New MAVENCLAD® Data at ACTRIMS Forum 2022 Show Favourable Efficacy Outcomes Versus Other Oral DMTs and Lower Occurrence of Further Relapses or Disability Progression

Merck, a leading science and technology company, today announced new real-world data from the MSBase Registry demonstrating MAVENCLAD® (cladribine tablets) had more favourable relapse outcomes and longer time to switch to another disease modifying...

2022년 2월 21일 11:55

European Commission Approves TEPMETKO® (tepotinib) for Patients with Advanced NSCLC with METex14 Skipping Alterations

Merck, a leading science and technology company, today announced that the European Commission (EC) has approved once-daily oral TEPMETKO® (tepotinib) as monotherapy for the treatment of adult patients with advanced non-small cell lung cancer (NSCL...

2022년 2월 21일 11:30

Long-Term Follow-Up Data Reinforce Continued Overall Survival Benefit of BAVENCIO® (avelumab) First-Line Maintenance Treatment in Patients with Advanced Urothelial Carcinoma

Merck, a leading science and technology company, today announced the results of an exploratory analysis from the Phase III JAVELIN Bladder 100 trial with 19 additional months of follow-up data from the initial primary analysis. This analysis reinf...

2021년 12월 21일 11:05

Merck Expands Neuroinflammatory Pipeline with Acquisition of Chord Therapeutics

Merck, a leading science and technology company, today announced a strategically focused expansion of its neurology pipeline with the acquisition of the rights to develop cladribine for the treatment of generalized myasthenia gravis (gMG) and neur...

2021년 12월 20일 14:15

TEPMETKO® (tepotinib) Receives Positive CHMP Opinion for Patients with Advanced NSCLC with METex14 Skipping Alterations

Merck, a leading science and technology company, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending approval of once-daily oral TEPMETKO® (t...

2021년 11월 22일 17:40

Merck Highlights Novel Mechanisms with the Potential to Transform Standards of Care in Several Cancers, MS, and Lupus

Merck, a leading science and technology company, today provided an overview of its innovative pipeline with a focus on five mid- to late-stage assets with first-in-class and/or best-in-class potential at its R&D Update Call. “At Merck we are worki...

2021년 10월 15일 17:10

New Data Presented at ECTRIMS Show Evobrutinib is First BTK Inhibitor to Demonstrate a Significant Reduction in Slowly Expanding Lesions (SEL) in Patients with RMS

Merck, a leading science and technology company, today shared data in an oral presentation from a Phase II post-hoc analysis, demonstrating that the oral, central nervous system (CNS)-penetrant, fully covalent Bruton’s tyrosine kinase inhibitor (B...

2021년 10월 14일 11:30

New Real-World MAVENCLAD® Data Show Sustained Effectiveness and Benefit on Quality-of-Life Measures in RMS Patients

Merck, a leading science and technology company, today announced new interim real-world data on MAVENCLAD® (cladribine tablets) that show patients with relapsing multiple sclerosis (RMS) experienced a significant improvement in quality-of-life (Qo...

2021년 10월 5일 16:30

Merck Completes Enrolment of Evobrutinib Phase III Clinical Trials Ahead of ECTRIMS 2021

Merck, a leading science and technology company, today announced enrolment has been completed in the Phase III EVOLUTION RMS clinical trial programme, which is evaluating the efficacy and safety of investigational Bruton’s tyrosine kinase (BTK) in...

2021년 9월 13일 10:30

Merck to Present Latest Highlights From Oncology Portfolio at WCLC and ESMO 2021

Merck, a leading science and technology company, today announced research from Company-sponsored, investigator-sponsored, and collaborative studies — including two oral and two mini-oral presentations — at this year’s World Conference on Lung Canc...

2021년 5월 21일 11:50

Data from Merck’s Oncology Portfolio Highlight Significant Advances in Cancer Care at ASCO21

Not intended for UK-, US- or Canada-based media Merck, a leading science and technology company, today announced 40 abstracts, including seven oral presentations and seven poster discussions, from Company- and investigator-sponsored studies (ISS) ...

2021년 5월 21일 11:50

머크, 2021 ASCO서 종양학 포트폴리오 데이터 공개해 암 치료 진전 조명

선도적 과학·기술 기업 머크(Merck)가 2021년 6월 4일부터 8일까지 개최되는 2021 미국임상종약학회(American Society of Clinical Oncology, ASCO)의 연례 회의에서 논문 초록 40건을 구두·포스터 프레젠테이션 등으로 발표할 예정이라고 19일 발표했다. 기업 주도 ...

2021년 4월 26일 10:20

Merck Announces New Data Strengthening Evidence for Continued Safe and Effective MAVENCLAD® Use During the COVID-19 Pandemic

Not intended for UK and U.S. based media Merck, a leading science and technology company, today announced a new analysis from the MAGNIFY-MS sub-study showing a specific immune repopulation pattern in patients with relapsing multiple sclerosis (RM...

Merck KGaA 보도자료

Merck KGaA 보도자료

Merck KGaA

회사 보도자료 구독